Agreement between Sponsor and Principal Investigator
Concerning Evaluation of Sponsor Confidential Information

In connection with a proposed clinical trial sponsored by [Insert name of clinical trial sponsor] ("Sponsor") titled [Insert title of the study] ("Study"), Sponsor desires to provide [Insert name of possible Principal Investigator] ("Investigator") with certain information pertaining to the Study or compound [insert name of compound] ("Study Drug") which Sponsor considers confidential in order for Investigator to evaluate the information and consider whether to conduct the Study.

1. For purposes of this Agreement, "Confidential Information" means only confidential information of Sponsor specifically related to the Study Drug or to the Study that is disclosed to the Investigator by Sponsor in writing and conspicuously marked as confidential and proprietary at the time of disclosure, or, if disclosed visually or orally, is stated to be confidential and proprietary at the time of disclosure and confirmed by a written summary describing the information in reasonable detail delivered by Sponsor to Investigator within seven (7) days after disclosure. Notwithstanding anything to the contrary contained in this Agreement or the markings on any document disclosed by Sponsor, Confidential Information does not include information that:

   (a) is in the public domain at the time Sponsor discloses it to Investigator or that thereafter enters the public domain through no fault of Investigator;

   (b) was known to Investigator or to the University of Pennsylvania ("University") before the date Sponsor discloses it to Investigator, or that becomes known to Investigator or the University through a third party having an apparent bona fide right to disclose the information;

   (c) is independently developed by University personnel;

   (d) is disclosed by Investigator or the University in accordance with the terms of Sponsor's written approval;

   (e) is required to be disclosed for compliance with any Federal, state or local law or regulation, or required to be disclosed by a court of law or governmental authority.

2. The Investigator shall use Confidential Information solely to evaluate the information and determine whether to conduct the Study. The Investigator retains the right to refuse to accept any Confidential Information that the Investigator does not consider to be essential to the performance of the Study.

3. For a period of three (3) years after Investigator's acceptance of Confidential Information or until a Clinical Trial Agreement is executed between the Investigator, the University and the Sponsor, whichever is shorter, Investigator agrees to use efforts no less than those Investigator employs with respect to Investigator's own confidential information to limit disclosure of the Confidential Information solely to those persons who have a need to review the Confidential Information in order to assist the Investigator in evaluating the Confidential Information and in deciding whether to conduct the Study and who have been informed of the confidential nature of the information.

4. This Agreement sets forth the entire understanding of Sponsor and Investigator with respect to the subject matter hereof, supersedes any prior agreement between Sponsor and Investigator, and there are no other understandings or agreements, written or oral, between them relating to such
subject matter. The Agreement may not be changed or supplemented in any way except by a
written agreement duly executed by both Sponsor and Investigator. This Agreement shall be
governed by, enforced and interpreted in accordance with the laws of the Commonwealth of
Pennsylvania, without giving effect to its principles of conflict of laws.

SPONSOR

______________________________

Date: _______________________

INVESTIGATOR

______________________________

Date: _______________________